share_log
Reuters ·  Mar 10 11:41
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a Ror1-Targeted ADC
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 336

Recommended

Write a comment